Validation of the Chinese Version of Oxford Depression Questionnaire

• Sponsor: First Affiliated Hospital of Zhejiang University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05535270
• Collaborator: (none)
• Enrollment: 272
• Location: 1
• Anticipated Duration (Months): 20.9
• Patients Per Site Per Month: 13

Study Details

Study Description

Brief Summary

Mood disorders are a group of psychiatric disorders that can affect a person's mood, energy, and motivation. Emotional blunting has been observed in clinical practice in patients with mood disorders. Emotional blunting has a negative impact on patients' overall treatment and leads to poorer adherence. The Oxford Depression Questionnaire (ODQ) is a measuring instrument of emotional blunting. The ODQ is expected to be a scientifically valid tool for detecting emotional blunting. The ODQ has high construct validity and internal reliability. However, no scientific validity studies have been conducted on ODQ in Chinese population. Therefore, this study is intended to investigate the reliability and validity of the ODQ in Chinese patients with mood disorders.

Condition or Disease	Intervention/Treatment	Phase
Mood Disorders; Emotional Blunting	Diagnostic Test: Oxford Depression Questionnaire (ODQ)

Study Design

• Study Type: Observational
• Anticipated Enrollment: 272 participants
• Observational Model: Cohort
• Time Perspective: Cross-Sectional
• Official Title: Psychometric Properties of the Oxford Depression Questionnaire in Chinese Patients With Mood Disorders
• Actual Study Start Date: Oct 1, 2021
• Anticipated Primary Completion Date: Nov 1, 2022
• Anticipated Study Completion Date: Jun 30, 2023

Arms and Interventions

Arm	Intervention/Treatment
Mood Disorder patients The participants completed a demographic questionnaire, the self-report Oxford Depression Questionnaire (ODQ-C), the Beck Depression Inventory-II(BDI-II), and the Montgomery-Asberg Depression Rating Scale (MADRS).	Diagnostic Test: Oxford Depression Questionnaire (ODQ); The Oxford Depression Questionnaire (ODQ)is a patient-centered questionnaire. The scale contains three sections: i) the patient's experience in the past week; ii) the patient's experience before the illness worsened, and iii) the patient's emotional feelings about receiving antidepressant treatment. The 26-item questionnaire contains four dimensions of "emotional blunting": not caring (NC), emotional detachment from others (ED), reduction in positive emotions (RP), and general reduction in emotions (GR). Patients not taking antidepressants were only required to rate the first two sections .
Healthy Controls The participants completed a demographic questionnaire, Patient Health Questionnaire - 9(PHQ-9), and the first two sections of Oxford Depression Questionnaire (ODQ-20).	Diagnostic Test: Oxford Depression Questionnaire (ODQ); The Oxford Depression Questionnaire (ODQ)is a patient-centered questionnaire. The scale contains three sections: i) the patient's experience in the past week; ii) the patient's experience before the illness worsened, and iii) the patient's emotional feelings about receiving antidepressant treatment. The 26-item questionnaire contains four dimensions of "emotional blunting": not caring (NC), emotional detachment from others (ED), reduction in positive emotions (RP), and general reduction in emotions (GR). Patients not taking antidepressants were only required to rate the first two sections .

Outcome Measures

Primary Outcome Measures

1. Oxford Depression Questionnaire (ODQ) [baseline]

   To analyze reliability and validity of the ODQ.

Secondary Outcome Measures

1. Beck Depression Inventory-II (BDI-II) [baseline]

   To analyze criterion validity of the Chinese version of the ODQ

2. Montgomery-Asberg Depression Rating Scale (MADRS) [baseline]

   To analyze correlation with ODQ

3. Oxford Depression Questionnaire (ODQ) [2 weeks after baseline]

   To analyze Test-retest reliability coefficients of the ODQ.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 13 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. both biological parents were Han Chinese; 2) currently diagnosed with major depressive disorder or bipolar disorder according to the Mini International Neuropsychiatric Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; 3) aged 13-65 years; 4) can complete the self-assessment questionnaires.

Exclusion Criteria:

1. currently diagnosed with neurological diseases or other major psychiatric disorders, e.g., schizophrenia, cognitive impairment, substance abuse; 2) diagnosed with severe somatic illnesses, such as diabetes and cardiovascular diseases;

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Department of Psychiatry, First Affiliated Hospital of Zhejiang University	Hangzhou	Zhejiang	China	310000

Sponsors and Collaborators

• First Affiliated Hospital of Zhejiang University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hu ShaoHua, Head of Department of Psychiatry, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Zhejiang University
• ClinicalTrials.gov Identifier: NCT05535270
• Other Study ID Numbers: IIT20220240B-R1
• First Posted: Sep 10, 2022
• Last Update Posted: Sep 10, 2022
• Last Verified: Sep 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Mood Disorders

Study Results

No Results Posted as of Sep 10, 2022